Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,852Revenue (TTM) $M147Net Margin (%)-70.2Altman Z-Score1.1
Enterprise Value $M1,864EPS (TTM) $-0.8Operating Margin %-56.7Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.6Pre-tax Margin (%)-69.4Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %1.4Quick Ratio4.4Cash flow > EarningsY
Price/Sales12.45-y EBITDA Growth Rate %9.6Current Ratio4.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-38.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-1,358.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M130ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

HALO is held by these investors:



HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-21.52view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-21.52view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-35.57view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.33-11.74view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.952.02view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.9251.68view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.9635.84view
Engler RobertDirector 2014-08-14Sell35,000$9.9635.84view
Engler RobertDirector 2014-05-15Sell126,700$7.5678.97view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.1348.19view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
Abbvie Ends Development Program With Halozyme Nov 21 2016 
First Eagle Fund of America 3rd Quarter Commentary Oct 28 2016 
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
ETFs with exposure to Halozyme Therapeutics, Inc. : March 6, 2017 Mar 06 2017
HALOZYME THERAPEUTICS INC Financials Mar 04 2017
Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Edited Transcript of HALO earnings conference call or presentation 28-Feb-17 9:30pm GMT Mar 01 2017
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 28 2017
HALOZYME THERAPEUTICS INC Files SEC form 10-K, Annual Report Feb 28 2017
Halozyme Therapeutics reports 4Q loss Feb 28 2017
Halozyme Therapeutics reports 4Q loss Feb 28 2017
4:10 pm Halozyme Therapeutics beats by $0.09, beats on revs; reaffirms FY17 revs guidance Feb 28 2017
Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results Feb 28 2017
Q4 2016 Halozyme Therapeutics Inc Earnings Release - After Market Close Feb 28 2017
Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season Feb 27 2017
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences Feb 23 2017
MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 Feb 13 2017
Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call Feb 01 2017
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US :... Jan 27 2017
ETFs with exposure to Halozyme Therapeutics, Inc. : January 17, 2017 Jan 17 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)